Oligohydramnios is associated with an increased risk of perinatal morbidity and mortality.
oligohydramnios have been studied, 5, 6 limited data are available regarding misoprostol for induction of labor in the setting of oligohydramnios. Misoprostol is associated with tachysystole with or without fetal heart rate changes compared with prostaglandin E2 and oxytocin. 7 Because oligohydramnios is associated with fetal heart rate decelerations during labor 1,2,8 and cesarean delivery, 8, 9 we hypothesized that use of misoprostol compared with prostaglandin E2 was associated with increased risk of cesarean delivery in women with oligohydramnios and an unfavorable cervix. The aim of this study was to evaluate maternal and neonatal outcomes in women with oligohydramnios undergoing induction of labor with misoprostol compared with prostaglandin E2.
Methods
The Consortium on Safe Labor (CSL) was a retrospective cohort study of all women delivering at ! 23 weeks of gestation between 2002 and 2008 (87% of births occurred in [2005] [2006] [2007] ) at 12 sites in 19 hospitals across 9 ACOG U.S. districts. 10 All participating institutions obtained institutional review board approval for the initial study. Data were available for a total of 228,562 mothers with 233,736 newborns. Participating institutions extracted detailed data on maternal demographics, medical history, labor and delivery summary, and neonatal information. Data were abstracted and mapped to predefined categories at the data coordinating center where data cleaning and logic checks were performed. Sites validated four outcomes including cesarean delivery for nonreassuring fetal heart rate tracing, asphyxia, neonatal intensive care unit (NICU) admission due to a respiratory diagnosis, and shoulder dystocia. Data collected from electronic medical records were compared with information extracted from medical charts. High concordance was noted (greater than 95% for 16 out of 20 variables and greater than or equal to 91.9% for all 20 variables).
10
We limited the analysis to women with a singleton gestation, delivery ! 36 weeks of gestation and no prior uterine scar. We excluded women without labor induction, multiple pregnancies, premature rupture of membranes, previous cesarean delivery, congenital or chromosomal abnormalities, and antepartum stillbirth. Induction of labor was determined according to documentation recorded in the medical chart along with the reason for admission. We limited the analysis to women with oligohydramnios, an unfavorable cervix, and known cervical exam. Oligohydramnios was recorded in the medical chart. In the CSL, ultrasound data such as an amniotic fluid index or maximal vertical pockets were not available. We calculated a simplified Bishop score using cervical dilation, effacement, and station (ranging, 0-9) to determine the ripeness of cervix. 11 We defined an unfavorable cervix as a simplified Bishop score 4, which has similar sensitivity and specificity to the original Bishop score 6 defining an unfavorable cervix. 11 To avoid intraperson correlation, we selected the first delivery from each woman in the database. Women could have also received oxytocin, underwent mechanical dilation, or had artificial rupture of membranes during the course of induction, but women who were missing the method of induction, who received both misoprostol and prostaglandin E2, or neither were excluded. The final analysis was limited to 358 deliveries (►Fig. 1). Information on maternal demographics, pregnancy outcomes, and induction agents was summarized. We investigated maternal outcomes including cesarean delivery, cesarean delivery indications (nonreassuring fetal heart tracing, failure to progress or cephalopelvic disproportion, and failed induction), operative delivery, induction to delivery time, chorioamnionitis, endometritis, postpartum hemorrhage, and transfusion by induction method for misoprostol compared with prostaglandin E2. We also investigated neonatal outcomes including NICU admission, NICU stay more than 72 hours, need for mechanical ventilation, and neonatal sepsis.
Descriptive statistics were calculated for all study variables. Bivariate analyses were performed with chi-square, Fisher exact, or Wilcoxon rank-sum tests. Multivariable logistic regression models or log-linear models, when appropriate, were performed to evaluate the net effect of the use of misoprostol compared with the use of prostaglandins E2, controlling for maternal age, maternal body mass index (kg/m 2 ), parity, and mechanical dilation. Gestational age at delivery and hypertension were not included in the models as our prior analysis showed no net effect of each on the outcomes of interest. The adjusted odds ratios (aORs) with corresponding 95% confidence intervals (CI) or the adjusted p-values were calculated. All statistical analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC).
Results
Maternal characteristics are presented in ►Table 1. Of 358 women with oligohydramnios and an unfavorable cervix undergoing induction with either misoprostol or prostaglandin E2, 141 (39.4%) received misoprostol and 217 (60.6%) received prostaglandin E2. Compared with those who received prostaglandin E2, women who received misoprostol were more likely to have public insurance or self-pay (p ¼ 0.02) and have mechanical dilation (p < 0.01).
Maternal and neonatal outcomes in women with oligohydramnios and an unfavorable cervix undergoing induction are presented in ►Table 2. There were no differences in cesarean delivery, cesarean indications, operative delivery, chorioamnionitis, postpartum hemorrhage, transfusion, NICU admission, NICU stay > 72 hours, mechanical ventilation, and neonatal sepsis between the two groups. Endometritis occurred in 4.3% of women undergoing induction with misoprostol compared with no events for induction with prostaglandin E2 (p < 0.05). There was no difference in induction to delivery time.
Comment
Our study found that maternal and neonatal outcomes of induction of labor with misoprostol were comparable to those of prostaglandin E2 in women with oligohydramnios and an unfavorable cervix. The maternal and neonatal outcomes of misoprostol for cervical ripening in the general population have been studied. 4, 7 Compared with prostaglandin E2 and oxytocin, misoprostol is associated with more vaginal deliveries within 24 hours and more uterine tachysystole with or without fetal heart rate changes. 7 In a meta-analysis, misoprostol was not associated with an increased risk of cesarean delivery compared with prostaglandin E2. 7 In our study of women with oligohydramnios who underwent induction of labor with an unfavorable cervix, misoprostol was not associated with an increased risk of cesarean delivery compared with prostaglandin E2. Further, there were no increased adverse neonatal outcomes associated with induction of labor with misoprostol compared with prostaglandin E2. The preferred mode of cervical ripening for women with oligohydramnios has not been determined. Previous studies comparing women with oligohydramnios and women with a normal amniotic fluid level showed that cervical ripening with misoprostol 12 and prostaglandin E2 [13] [14] [15] was not associated with an increased risk of cesarean delivery or adverse neonatal outcomes. In addition, no differences in cesarean delivery rates have been reported in studies comparing prostaglandin E2 and mechanical dilation in women with oligohydramnios. 5, 6 A previous meta-analysis found that misoprostol was associated with an increased risk of Abbreviations: aOR, adjusted odds ratio; CI, confidence intervals; FTP/CPD, failure to progress or cephalopelvic disproportion; NA, not available; NICU, neonatal intensive care unit; NRFHT, nonreassuring fetal heart tracing; SD, standard deviation. Note: Number shown as n (%) unless specified. Prostaglandin E2 (referent). a Adjusted odds ratios (aORs) were controlled for maternal age, body mass index at delivery, parity, and gestational age. b Women could have indications other than non-reassuring fetal heart tracing, failure to progress or cephalopelvic disproportion, or failed induction; thus totals are not 100%. c Due to missing data. d The adjusted p-value was estimated based on multivariable log-linear model. tachysystole compared with prostaglandin E2.
7 Because oligohydramnios is associated with increased risk of fetal heart rate decelerations during labor, 1,2,8 a hypothetical concern is an increased risk of cesarean delivery in women undergoing induction of labor with misoprostol. However, it was reassuring that our study did not demonstrate an increased risk of cesarean delivery associated with misoprostol compared with prostaglandin E2 when used in women with oligohydramnios with an unfavorable cervix. Our study found an increased rate for endometritis in women with an unfavorable cervix undergoing induction of labor with misoprostol compared with prostaglandin E2. The reason for the increased risk of endometritis is unclear and this increased rate might be chance. Previous small studies comparing misoprostol and oxytocin did not find increased risks for endometritis with misoprostol.
16,17 However, our study was not large enough to perform a multivariable logistic regression study to evaluate for confounders such as number of cervical examination. Larger prospective studies are needed to evaluate the risks for endometritis in women with oligohydramnios undergoing induction of labor with misoprostol. Limitations of our study include the retrospective nature of the analysis and variability of definitions for oligohydramnios across clinical sites. Ultrasound data such as an amniotic fluid index or maximal vertical pockets were not available in this study. Due to the lack of ultrasound data, there is a risk of misclassification. Another limitation is that induction protocols varied across the study sites. Providers were aware of the diagnosis of oligohydramnios. Due to the lack of data regarding maternal and neonatal outcomes associated with misoprostol in women with oligohydramnios, some providers may have chosen not to use misoprostol. Also, we did not have information on the dose of misoprostol or the route of administration. Because 50 mg of misoprostol compared with 25 mg causes more tachysystole 18 and ACOG recommends the use of 25 mg, 4 we suspect that 25 mg of misoprostol was used in the majority of inductions in the CSL. Similarly, we assume that vaginal administration was the most likely route used since ACOG has not endorsed buccal or oral routes for misoprostol until further studies support their safety. 4 It is also possible that our findings may be explained by selection of women for a particular induction agent that was based on unmeasured factors rather than the induction agent itself. However, we only included women with an unfavorable cervix to limit the selection bias. Lastly, due to the small sample size, there is a chance of type II error. Given the clinical data from a diverse U.S. population, our findings are more widely applicable. Further, our data on misoprostol in women with oligohydramnios are novel.
In conclusion, misoprostol use for labor induction in women with an unfavorable cervix was not associated with an increased risk of cesarean delivery in the setting of oligohydramnios compared with prostaglandin E2. Prospective randomized studies are needed to better evaluate the maternal and neonatal outcomes of misoprostol compared with prostaglandin E2 in women with oligohydramnios and an unfavorable cervix. 
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